OUR DISCOVERY TECHNOLOGY

Logo background removed.png

COMPASS

COMPASS is composed of a mass spectrometry protocol and AI software.  It has achieved: 

  • Identification of biomarkers that predict onset of Preeclampsia and Preterm Birth, and which diagnose or stage Alzheimer's Disease, Endometriosis, and Breast Cancer metastasis 

HIGH-CONTENT INFORMATION IN  SERUM: Our unique data source

The contents of the blood are a window into the health of the organism

The story is told by the biomolecule products of ongoing cellular processes

As health status alters cellular process activity, expression of biomolecule products changes

Our COMPASS technology was developed to detect and exploit these expression changes

The advantages of COMPASS:

  • Considers a large number of unique species: >120,000 peptides, small molecules, and lipids

  • Unlike DNA, whose information if fixed. The information analyzed by COMPASS is dynamic and reflects changing health status

  • COMPASS is agnostic to biological function, allowing exploitation of biomarkers that have not been previously characterized

COMPASS Process

1.

DRAW BLOOD, PROCESS TO SERUM

Simple blood draw and conversion to serum

2.

RECOVER HIGH-INFORMATION BIOMOLECULES 

There are approximately 30 highly abundant , low-information molecules that occur more that 10 million times more frequently in serum than high-information molecules. These are removed according to Magellan's licensed protocol

3.

ANALYZE BY MASS SPECTROMETRY

Mass spectrometry identifies molecular mass (m/z) and retention time (rt) for the remaining high-information biomolecules. The result is quantitative expression data for each high-information species.

4.

INTEGRATE MASS SPEC DATA WITH PATIENT DATA

The mass-spec output is then integrate with patient health information, including treatment outcomes. We can integrate other data types, including the outcomes of other analyses.

5.

APPLY MACHINE LEARNING TO DEVELOP A PREDICTIVE MARKER SET

Our proprietary algorithms are applied to the combined data set. We deliver: 1) a list all differentially expressed species, and 2) a trained  machine learning classifier , including which specific species are critical to its decisionmaking. We can also perform molecular identification of these species, revealing biological connections.

Discovery Process

The standard approach for discovering predictive markers usually follows these steps:

 

  1. Study the biology of the condition

  2. Identify one or more molecules that are critical to the process

  3. Develop an assay for detecting the identified molecules

  4. Use the assay to try to predict the desired condition

  5. If this did not work, restart at step 1

The above process requires significant biological skill, capabilities, time, and expense

 

The Magellan approach works differently:

 

  1. Identify a set of patient the exhibit the condition or may exhibit the condition in the future, as well as a set of control patients

  2. Extract blood, produce serum and perform Magellan's mass-spec analysis on all patients

  3. Using machine learning, analyze >120,000 unique species, and develop a classifier for the desired outcome

In some cases, the identity of the markers can be elucidated by further mass-spec analysis.   

 

The Magellan method does not require an underlying understanding of the biology, is target agnostic, and is faster, less expensive than traditional approaches.

© 2018 by Magellan Bioanalytics